Navigation Links
New MedPredict Report Highlights Trend Toward Early Diagnosis and Treatment of Rheumatoid Arthritis, Impact on Pharmaceutical Development
Date:7/8/2008

SCOTTSDALE, Ariz., July 8 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for Rheumatoid Arthritis (RA) therapies.

In this report, entitled Thought Leader Insight & Analysis: Rheumatoid Arthritis Q2 2008, MedPredict's global Thought Leader Panel reviews progress in developing biological and small molecule regimens for the treatment of early RA.

According to this report, the key change in practice occurring in the treatment of RA is the push toward earlier diagnosis and treatment, which is associated with more durable remission. New biomarkers and approaches to cellular imaging in early disease are also being investigated.

"Our Panel sheds light on which companies are likely to be positioned to capitalize on this trend," says MedPredict President Jeffrey D. Berk. "In addition, they offer predictions on how tocilizumab, certolizumab and golimumab will compete with the established biologicals, and how the current market leaders are positioning to defend their brands in the RA space. Their discussion will provide essential strategic and competitive insight for anyone with a stake in this market."

The report also addresses pain management in RA, provides a postmortem on the rituximab non-renal lupus trial, and discusses the most meaningful clinical developments related to the following mechanisms: Anti-TNF, Anti-CTLA, Anti-IL-1, Anti-IL-6, Antiresorptives, Anti-IL-17, p38 MAP kinase, JAK, Syk, PDE5, and more.

Companies mentioned in this report include: Abbott, Amgen, Amgen/Takeda Bio, Amgen/Wyeth, AstraZeneca/MedImmune, Biogen, Bristol-Myers Squibb, Celgene, Centocor, Centocor/Schering-Plough/Essex, GlaxoSmithKline/Genmab, Human Genome Sciences, Incyte, Merck Serono/ZymoGenetics, Novartis, Oxypharma, Pfizer, Roche/Chugai, Roche/Genentech, Sanofi-Aventis/Regeneron, UCB, Vertex and Wyeth/Trubion.

MedPredict conducted in-depth, primary interviews with leading rheumatologists from North America and Europe to provide the basis for this report.

This report can be purchased by contacting MedPredict.

About MedPredict

MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.


'/>"/>
SOURCE MedPredict Market Research
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. In Pain Market, Huge Unmet Needs, Tough Regulatory Environment Challenge Pharmaceutical Companies, According to MedPredict
2. Thought Leaders Discuss Positive Outlook for Bapineuzumab in Alzheimers Disease in MedPredict Report
3. New MedPredict Report Suggests Market for Alcoholism Therapies is Underestimated
4. Unmet Needs Provide Challenges and Opportunities for Rheumatoid Arthritis Drug Developers According to MedPredict Report
5. Pipeline for Lung Cancer Therapies is Focus of New MedPredict Report
6. Knowledge Enterprises, Inc. and The Institute for Orthopaedics(TM) Release The 2007-2008 Orthopaedic Industry Annual Report
7. Galaxy Nutritional Foods Reports FY2008 Results
8. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
9. Cyberonics Reports Strong Revenue Growth and Profitability in Fiscal 2008 Fourth Quarter
10. Alfacell Reports Financial Results for Third Quarter of Fiscal 2008
11. Dermatologists Report Increased Use of Biologics in the Treatment of Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... UTAH. (PRWEB) , ... May 25, 2016 , ... WEDI, ... healthcare information exchange, today announced that Charles W. Stellar has been named by the ... interim CEO since January 2016. As an executive leader with more than 35 years ...
(Date:5/24/2016)... ... , ... Last week, Callan Capital, an integrated wealth management firm specializing in ... San Diego Life Science event at the Estancia La Jolla Resort and Spa. , ... speakers Dr. Rich Heyman, former CEO of Aragon and Seragon, and Faheem Hasnain, former ...
(Date:5/23/2016)... , May 23, 2016 Oxitec CEO ... th at 10:15 a.m. ET before the United States ... genetically engineered mosquitos can play in controlling the spread of ... the Zika virus.      (Logo: http://photos.prnewswire.com/prnh/20150630/227348 ... mosquito with a self-limiting gene. Trials in Brazil ...
(Date:5/20/2016)... ... May 20, 2016 , ... The leading Regenerative Veterinary ... most experienced veterinary clients have treated over 100 of their own patients with the ... provide the highest level of care for their patients. , The veterinarians are ...
Breaking Biology Technology:
(Date:3/14/2016)... 2016 NXTD ) ("NXT-ID" or the ... announces the airing of a new series of commercials on ... March 21 st .  The commercials will air on Bloomberg ... on the Street show. --> NXTD ) ("NXT-ID" ... commerce market, announces the airing of a new series of ...
(Date:3/11/2016)... 11, 2016 http://www.apimages.com ) - --> ... is available at AP Images ( http://www.apimages.com ) - ... used to produce the new refugee identity cards. DERMALOG will be ... CeBIT in Hanover next week.   --> ... be used to produce the new refugee identity cards. DERMALOG will ...
(Date:3/10/2016)... 2016 --> ... "Identity and Access Management Market by Component (Provisioning, Directory ... by Organization Size, by Deployment, by Vertical, and by ... The market is estimated to grow from USD 7.20 ... at a Compound Annual Growth Rate (CAGR) of 12.2% ...
Breaking Biology News(10 mins):